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COUNCIL DECISION 
of 
on a specific research and 
technological development programme 
in the field of biotechnology (1990-1994) 
BRIDGE 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having regard to the Treaty establishing the European Economic 
Community, and in particular Article 130q(2) thereof, 
( 1 ) 
Having regard to the proposal from the Commission 
( 2) 
In co-operation with the European Parliament , 
, 
Having regard to the Opinion of the Economic and Social 
Committee <3 >, 
(1) OJ N° C 70 of 20.3.1989, p. 1. 
(2) Opinion of 24 May 1989 (not yet published in the Official 
Journal) and Decision of ... (not yet published in the 
Official Journal). 
(3) Opinion of 27 April 1989 (not yet published in the Official 
Journal). 
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Whereas Article 130k of the Treaty stipulates that the 
Framework Programme shall be implemented through specific· 
programmes developed within each activity; 
Whereas, by its Decision 87/516/Euratom/EEC <1 >, as amended by 
Decision 88/193/EEC,Euratom <2 >, the Co~ncil has adopted a 
Framework Programme for Community activities in the field of 
research and technological development (1987-1991), providing 
inter alia for activities ensuring the exploitation and optimum 
use of biological resources; 
Whereas that Decision provides that a particular aim of 
Community research must be to strengthen the scientific and 
technological basis of European industry, particularly in 
strategic sectors of advanced technology, and to encourage it 
to become more competitive at the international level, and 
that Community action is justified where research contributes, 
inter alia, to the strengthening of the economic and social 
cohesion of the Community and to the promotion of its overall 
harmonious development, while being consistent with the pursuit 
of scientific and technical excellence; whereas the 
Biotechnology Research for Innovation, Development and Growth 
in Europe (BRIDGE) programme should contribute to the 
achievement of these objectives; 
Whereas the activities provided for in the Framework Programme 
include, in particular: 
(1) OJ No L 302, 24.10.1987, p. 1. 
(2) OJ No L 89, 6. 4.1988, p. 35. 
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- the establishment of Community research· and development 
(R & D) for contributing a transnational dimension to 
national efforts and for facilitating technology transfer 
towards industry and agriculture in the areas of 
infrastructure, basic biotechnology and risk analysis, 
- the continuous evaluation of the strategic significance of 
new developments in biotechnology and promotion of the 
essential coherence between the different areas of Commun.ity 
policy concerned with biotechnology; 
Whereas Decision 81/1032/EEC <1 > adopting the multiannual 
research and training programme for the European Economic 
Community in the field of biomolecular engineering and Decision 
85/195/ C <2 > d . d . . 88/420/ C <
3 > .. EE a opting, an Dec1s1on EE rev1s1ng, 
the multiannual research action programme for the European 
Economic Community in the field of biotechnology 
(1985-1989) have clearly demonstrated the utility of Community 
actions in biotechnology and the need for their expansion; 
Whereas particular attention should be paid to ethical and 
social matters which may be associated with this programme. 
Whereas the participation of European non-Member States wholly 
or partially with projects in. this programme is desirable; 
( 1 ) OJ No L 375, 20.12.1981, p . 1 . 
( 2) OJ No L 83, 23. 3.1985, p. 1 . 
( 3) OJ No L 206, 30. 7.1988, p. 38. 
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Whereas it is desirable to involve small and medium-sized 
e n t e r p r i s e s t o t h e ma x i m um e x t e n t po s s i b l e i n t h e b i o· t e c h n,o: L o~g y. 
research and development programme; 
Whereas the implementation of research and training actions in 
the COST framework is an essential element to complement R&D 
projects in the field of biotechnology; 
Whereas the Scientific and Technical Research Committee (CREST). 
has given its opinion; 
HAS ADOPTED THIS DECISION: 
Article 1 
A specific research and technological development programme 
(BRIDGE) for the European Economic Community in the field of 
biotechnology, as defined in Annex I, is hereby adopted for a 
period of four years from 1 January 1990. 
Article 2 
The funds estimated as necessary for the execution of the 
programme amount to ECU 100 million, including expenditure on a 
staff of 28. 
An indicative allocation of funds is set out in Annex II. 
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Article 3 
Detailed rules for the implementation of the programme and the 
rate of the Community's financial participation are set out in 
Annex I. 
Article 4 
1. In the third year of implementation of the programme, the 
Commission shall review it and send a report on the results of 
its review to the European Parliament and the Council. This 
report shall be accompanied, where necessary, by proposals for 
amendment or extension of the programme. 
2. At the end of the programme, an evaluation of the results 
achieved shall be conducted by the Commission, which shall 
report thereon to the European Parliament and the Council. 
3. The abovementioned reports shall be established having 
regard to the objectives and criteria set out in Annex III to 
this Decision and in accordance with Article 2(2) of Decision 
87/516/Euratom,EEC. 
Article 5 
The Commission shall be responsible for the execution of the 
programme. 
The Commission shall be assisted by a Committee of an advisory 
nature, hereinafter referred to as "the Committee", composed of 
the representatives of the Member States and chaired by the 
representative of the Commission. 
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Contracts concluded by the Commission shall govern the rights· 
and obligations of each party, in particular the arrangements 
for the dissemination, protection and exploitation of research 
results. 
Article 6 
1. The representative of the tommission shall submit to the 
Committee a draft of the measures to be taken. The Committee 
shall deliver its opinion within a time limit which the 
Chairman may lay down according to urgency of the matter, if 
necessary by taking a vote,. 
2. The opinion shall be recorded in the minutes of the 
Committee; in addition, each Member State shall have the right 
to have its position recorded in the minutes. 
3. The Commission shall take the utmost account of the opinion 
delivered by the Committee. It shall inform the Committee of 
the manner in which its opinion has been taken into account. 
Article 7 
The procedures Laid down in Article 6 shall apply 1n particular 
to: 
- the contents of the calls for proposals; 
- the assessment of the proposed projects and the estimated 
amount of the Community's contribution to them; 
- departures from the general rules governing Community 
participation set out in Annex I; 
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No contracting party based outside the Community~and. 
participating as a partner in a project undertaken under the 
programme may benefit from the Community financing for this 
progamme. Such contracting party shall contribute to the 
general administrative costs. 
Article 9 
This Decision is addressed to the Member States. 
Done at Brussels, 
7292/89 
For the Council 
The President 
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- the participation in any project by non-Community 
organisations and enterprises referred to in Article 8(2); 
- any adaptation of the indicative allocation of funds set out 
in Annex II; 
- the measures to be undertaken to evaluate the programme; 
- arrangements for the dissemination, protection and 
exploitation of the results of research carried out under the 
programme. 
Article 8 
1. The Commission is authorized to negotiate, in accordance 
with Article 130n of the Treaty, agreements with international 
organizations, those non-Member States participating in 
European Co-operation in the field of Scientific and 
Technological Research (COST) and those European countries 
having concluded framework agreements in scientific and 
technical co-operation with the Community, with a view to 
associating them wholly or partly with the programme. 
2. Where framework agreements for scientific and technical 
co-operation between European non-Member States and the 
European Communities have been concluded, organizations and 
enterprises established in those countries may, on the basis of 
the criterion of mutual benefit, become partners in a project 
undertaken within the programme. 
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U p d a t i n g a n d d e s i g n o f k n o w l e d g e b a s e s f o r s t o r i n g a n·d:. 
c l a s s i f y i n g b i o ( t e c h n o ) l o g i c a l d a t a s u c h a s s e q u e n c. e~s ·, 
g e n e t i c m a p s , p r o t e i n a n d b i o p o l y me r s t r u c t u r e s , r i s·k 
assessment data; 
Exploitation of existing or newly developed information 
technology for rapid access to European knowledge bases 
and closed sequencing networks via an electronic 
network, including electronic input, on-line catalogues, 
electronic ordering, etc. 
2. Enabling technologies 
2.1. Protein design/molecular modelling 
- Multidisciplinary approaches including genetic 
engineering and advanced structural methods aiming at 
improving the properties (such as stability, pH optimum, 
substrate specificity) of interesting proteins and their 
complexes (including glycoproteins); 
- Development of methods to understanding and predict 
structure/function relationships of proteins, such as 
those involved in folding, stability, crystallisation, 
including theoretical methods for simulation of these 
properties, and their interactions with other related 
molecules. 
2.2. Biotransformation 
- Development of biological reactions using new strains of 
cells or novel enzymes for synthesis of key 
intermediates needed for the production of high added 
value substances (particular attention to be given to 
the bioconversion of agricultural surpluses) and for 
converting pollutants to innocuous compounds; 
7292/89 
(ANNEX I) 
MO/mmk EN 
- 2 -
ANNEX I 
PROGRAMME CONTENTS AND IMPLEMENTATION 
AND THE RATE OF THE COMMUNITY'S FINANCIAL PARTICIPATION 
ACTION I: RESEARCH AND TRAINING 
CONTENT 
1. Information infrastructure 
1.1. Culture collections 
Development of a communication system for easy and rapid 
access to the most important service culture collections 
within the Community is to be achieved through support of: 
- a Promotion Centre for Culture Collections, specifically 
designed for providing to European users (distribution 
of catalogues, patent regulations, printed and visual 
material) adequate information on expertise and services 
available in different European Culture Collections; 
- a Centralised European Data Bank, primarily on 
microorganisms and subsequently extended to other biotic 
materials (animal and plant cells, viruses, plasmids). 
The first phase towards this objective to involve the 
harmonisation of formats and data in the main service 
culture collections of the European Community. 
1 . 2 . P r o c e s s i n g a n d a n a l y s e_ s o f b i 9. ( t e c h n o ) L o g i c a l d a t a 
- Applications of information technology (specialised 
software and equipment) such as required for the 
implementation of the activities in protein engineering 
and gene sequencing (see also 2.1. and 2.3.); 
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3. Cellular biology 
3.1. Physiology and molecular genetics of industrial 
microorganisms 
Gene stability and expression, post-translational 
processes, genetic and metabolic regulation of over-
production, transport and secretion. These studies, 
adapted in each case to the current state of the art, 
will concentrate on some industrially interest~ng 
microorganisms, such as the genera Lactic acid bacteria, 
Stretomyces, Pseudomonas, Bacillus, Clostridium, 
Corynebacterium, and including the larger groups of lactic 
acid bacteria~ extremophiles, yeasts and filamentous 
fungi. 
3.2. Basic biology of plants and associated organisms 
- Core processes for sexual breeding: mechanisms of flower 
initiation and evocation, differentiation of sex cells; 
molecular bases of gamete recognition and selection 
systems; 
- Fundamentals of plant cell regeneration: genetics and 
molecular biology of somatic and zygotic embryogenesis; 
perception and transduction of growth-promoting signals; 
7292/89 
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Research addressing the problem of genetic and 
physiological stability of the free or immobilised 
genetically modified microbes or cells under 
biotransformation conditions; 
- Research addressing the problem of enzymatic activity 
under extreme environments (organic solvents, pHs, 
temperatures, immobilisation); 
- Development of methods for the isolation and 
purification of biotransformation products (upstream and 
downstream processing); 
- Development of specialised software and mathematical 
modelling for the control and analysis of 
biotechnological processes. 
2.3. Gene mapping, genome sequencing, novel cloning methods 
- Sequencing the genome of yeast (Saccharomyces 
cerevisiae) or parts thereof and of Bacillus subtilis; 
- Development of molecular genetic techniques to identify 
new meaningful plant genes, using the Arabidopsis genome 
as a resource; characterisation of the identified genes; 
Development of advanced sequencing procedures and 
technology (see 1.2.) and integration of these' 
procedures and technology in the sequencing projects. 
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4.1. Safety assessments associated with the release of 
genetically engineered organisms 
- Monitoring and control techniques: sampling and probes 
for engineered organisms and introduced segments of DNA; 
methods and instrumentation for high resolution 
automated microbial identification and the establishment 
of adequate data bases; creation of a bank of specific 
probes and chemical signatures for a large number of 
specific microorganisms; eradication methods; 
- Assessment techniques: biological containment; gene 
stability and gene transfer; development of microcosms 
and simulating methods for impact analysis; 
- Acquisition of fundamental knowledge on gene behaviour 
(horizontal transfer between species, rearrangement of 
introduced genes in the host organism) and on the 
survival and adaptation of released organisms, in 
particular soil bacteria, and including modification of 
host range and tissue range for engineered viruses; 
- Novel constructions: biologically contained organisms; 
suicide vectors or constructions which cannot develop 
outside the host organism; engineered organisms which 
can be destroyed in the environment by known and 
specific techniques. 
4.2. In vitro evaluation of the toxicity and pharmacological 
activity of molecules 
- Development of cellular and multicellular systems as 
surrogates for in viva tissues and organs; 
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- Molecular interfaces of plants and associated organisms: 
molecular bases of host-range and virulence; characteri-
sation of plant defence reactions; development of 
genetic techniques for pathogenic fungi or mycorrhizae; 
regulation from plant/microbial signals of the 
expression of microbial/plant genes; structural and 
functional identification of genes involved in N2-fixing 
symbioses; 
- Physiological attributes of crops: storage processes; 
stress physiology; nitrogen use efficiency. 
3.3. Biotechnology of animal cells 
Animal cell engineering and culture technology Leading 
to new or improved productions of important substances 
for industrial and zootechnical purposes; 
Animal genetics: mapping and sequencing of important 
genes; methods of gene transfer; and study of gene 
expression and regulation on cell cultures; 
Animal husbandry: improved immunity through genetically 
engineered vaccines of second generation. 
4. Pre-normative research 
Prenormative research in biotechnology places itself at both 
ends of the research-development-exploitation chain. 
------------------- --------···-··-----
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For shared-cost contracts, the Community participation 
will be up to 50% of the total expenditure. Alternatively, in 
respect of universities and research institutes carrying out 
projects under this programme, the Community may bear up to 
100% of the additional expenditure involved. 
Two types of transnational research projects, which will 
normally be carried out by participants from more than one 
Member State (irrespective of participants from third 
countries), are foreseen: 
- N projects, for the integration in adapted Community 
structures (European Laboratories Without Walls: ELWW) of 
research efforts in areas where the main bottlenecks result 
from gaps in basic knowledge. The contribution of the 
Community in such projects shall not exceed ECU 400 OOO per 
year per project; 
- T projects, for the removal, through a significant investment 
of skills and resources, of important bottlenecks resulting 
from structural and scale constraints; the contribution of 
the Community in such projects may vary from 
ECU 1 to 3 million per year per project. 
Shared-cost research contracts shall be awarded following 
a selection procedure based on calls for proposals published in 
the Official Journal of the European Communitie~. 
Special attention wi Ll be paid to the dissemination of the 
programme results in accordance with Community rules and taking 
into account contractual arrangements in order to maximise the 
effects of this work and to allow all enterprises, particularly 
small and medium enterprises, in all regions of the Community, 
including the Less-favoured ones to benefit. 
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- Research addressing the problems of preparation, storage 
maintenance and growth of human cell cultures; 
Development of cell lines in which functional properties 
are better preserved. 
IMPLEMENTATION 
This part of the programme shall be implemented by means 
of training activities, research activities carried out on the 
basis of shared-cost research contracts, and participation in 
certain COST (Category A) activities. 
Training actions shall be implemented through training 
contracts and courses for any of the themes defined above. The 
cost of these actions shall be borne by the Community. 
Participants in a project conducted as a shared-cost 
action may be industrial enterprises, including small and 
medium enterprises, research institutions, universities or 
combinations of them, established in the Community or in those 
European third countries which have concluded framework 
agreements in scientific and technical co-operation with the 
Community. Pending the implementation of the provisions of a 
possible Council Directive on deliberate release into the 
environment of genetically modified organisms, proposals 
selected will have to conform, in the country where the release 
experiment is to take place, to relevant safety regulations or 
guidelines; in those countries where no such regulations or 
guidelines have been developed, the project proposers planning 
to initiate release experiments will ascertain that there is no 
objection from the competent authorities concerned. 
Shared cost research projects involving research centres 
(and/or universities) and industry are strongly encouraged. 
Industrial participation should constitute an important 
criterion of selection in the programme. 
-~-~-------------------------------------7292/89 
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COST ACTIVITIES (CATEGORY A) ASSOCIATED WITH ACTION I 
CONTENT 
- Marine primary biomass 
- In vitro-cultures for the purification and propogation of 
plants 
- Methods for early detection and identification of plant 
diseases 
- Vesicular-arbuscular (VA) mycorrhizae 
- Development of vaccines against coccidiosis. 
IMPLEMENTATION 
Implementation shall take place through the organisation 
of meetings, consultation of experts, publications, exchange of 
research workers between Laboratories, co-ordination contracts. 
ACTION II: CONCERTATION 
CONTENT 
In conjunction with the relevant Commission services and 
the Member States, the following tasks will be executed: 
Ci) Monitoring developments in biotechnology, particularly in 
the field of R&D, assessing their implications, and hence 
informing services of the Commission and interested 
public authorities having related responsibilities. 
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(ii> Identifying possible ways in which the contextual 
c o n d i t i o n s f o r t h e be n e f i c i a l de v e l op me n t o f b i o:-· · 
t e c h no l o g y i n E u rope ma y be i m p roved , a n d t he e ff e c ttv,e-
n e s sand coherence of Member State and Communfty 
biotechnology programmes and related policies enhanced, 
including those involving international collaboration. 
(iii) Disseminating knowledge and helping to increase public 
awareness and understanding of the nature, potential, and 
possible risks associated with biotechnology. 
(iv) Identifying the need for and helping to promote greater 
activity in the biotechnology small firm sector in the 
Community. 
IMPLEMENTATION 
The action will continue to develop the work (begun under 
BAP) of ad hoe collaboration between groups and individuals 
with interests and capabilities in the life sciences and 
biotechnology, so creating networks, as informal and flexible 
as possible, adapted to the needs of encouraging co-ordination 
through the exchange of information between the participants, 
and assisting the broader diffusion of information required by 
the above tasks. 
Specifically, the work will involve inhouse analysis, the 
setting-up and the exploitation of an organised information 
base, and missions. It will also include as necessary the 
commissioning of study reports, the organisation of workshops 
and meetings, and support for the production of reports and 
dissemination of information. 
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( 
An appropriate part of the resources of Action II, 
Concertation, will be devoted to actions concerning the wider 
implications of research and development in the areas of 
biotechnology - e.g. for consumers, Society, environment and 
development - featuring in Action I. 
7292/89 
(ANNEX I) 
MO/mmk EN 
- 11 -
ANNEX II 
INDICATIVE ALLOCATION OF FUNDS 
(millions of ecus) 
ACTION I: Research and training 
- Contract research 
(To be divided equally between 
N projects (ECU 38,25 million) and 
T projects (ECU 38,25 million)) 
= pre-normative research 
= cell biology 
= enabling technologies 
= information infrastructure 
- Training activities 
- COST activities 
ACTION II: Concertation 
15,5 
27,0 
27,0 
7,0 
(1) Of which approximately 9% staff costs. 
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3 . P a r t i c u l a r o b j e c t i v e s , t e s t a b l e i n 1 9 9 5 , t o be a t t a i'ne:ct· · · · 
4. 
through "N" projects including the following: 
3.1. constitution of networks for transnational co-operation 
in each of the four areas (information infrastructure; 
enabling technologies; cellular biology; prenormative 
research) of the programme; 
3.2. transnational co-operation as demonstrated through the 
analysis of scientific publications (each specific 
network or ELWW to produce at Least one paper, either 
with transnational authorship or with acknowledgement 
of materials/methods supplied by other contract 
partners); 
3.3. high quality of scientific achievements, as 
demonstrated through consultations of scientific 
experts and through analysis of citation records of 
scientific articles summarizing the results of the 
research; 
3.4. expression of industrial interest as underlined, at 
Least in 20% of the projects, by industrial involvement 
during the implementation phase or, outside the BRIDGE 
Legal framework, at the time of exploiting the results 
of the research. 
Particular objectives, to be attained through the 
constitution and implementation of "T" projects, include the 
following: 
4.1. setting out a description, in terms of research efforts 
and expected benefits, of specific targets, such as the 
sequencing of the yeast genome, high resolution 
automated microbical identification or molecular 
identification of new plant genes; 
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ANNEX III 
PROGRAMME OBJECTIVES AND EVALUATION CRITERIA 
The Commission's communication to the Council concerning a 
Community Plan of Action relating to the evaluation of 
Community research and development activities for the years 
1987-1991 CCOM(86) 660 final) state that the objectives and 
milestones of each research programme have to be set out in a 
testable form. The objectives and milestones of the programme 
are set out below. 
Action I: Research and training 
1. The long term objective is to contribute to the 
exploitation and the optimum use of biological resources in 
the Community, thus improving the research capabilities and 
infrastructures necessary for the competitiveness of 
European agriculture and biotechnology industry, and for the 
protection of the environment. This aim is to be pursued 
through the removal of scientific and technical bottlenecks 
rt::::>u~i..; •• ~ c;;_;.t:, fr-om gaps in knowledge or from scale and 
structural constraints. Research projects will be executed 
in the interactive way, making full use of integration 
between disciplines, bringing needs and opportunities in 
different Member States together, combining different 
expertises from basic and applied fields. 
2. The primary short term objectives are, therefore, to 
elicit proposals for research and for training activities on 
a scale commensurate with the Community resources proposed 
and, thereafter, to implement these activities ("N" 
projects, "T" projects, training, and co-operation with 
third countries) in such a way that multidisciplinary 
transnational co-operation and scientific mobility are 
vigorously promoted. 
1992-1993. 
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Action II: Concertation 
The evaluation of the concertation action will consid~r~ 
whether the programme has in fact implement~d the tasks 
specified in the Decision, and whether their implementation has~ 
effectively contributed to the stated objectives. More 
specific evaluation criteria are as follows: 
1. Concertation with Member States: the concertation 
action should have assisted those responsible for 
biotechnology in Member States' administrations: 
1.1. to be aware of current and planned Commission 
initiatives in areas relevant to biotechnology; 
1.2. to be aware of biotechnology activities and plans in 
other Member States; 
1.3. consequently, to have taken into account, in their 
national plans or initiatives for biotechnology, 
activities at Community Level or in other Member 
State~. 
2. Impact on the conditions for biotechnology in Europe: 
the concertation action should be examined to establish 
whether and to what extent it has contributed to improving 
the contextual conditions in Europe for the safe development 
and beneficial application of biotechnology; with particular 
reference to international competitiveness; to the formation 
and growth of small companies and to the climate of public 
opinion about biotechnology. 
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4.2. accomplishment, two years after initiation of a "T" 
project, of progress towards the specified targets 
(namely through having made the right provisions and 
commitments securing that scientific goals are 
attainable by the time the programme is completed); 
4.3. significant contributions indicating that the specified 
targets have been reached and that the specific 
interest of industry, agriculture or environmental 
control has been met. 
5. For the training programme, the aim is to provide 
fellowships in research laboratories of a high scientific 
level for approximately two years for junior scientists, and 
one to two years for senior scientists. Particular 
objectives are the following: 
5.1. accomplishment of a marketing effort in all Community 
Member States; 
5.2. return of most fellows, after their training period, to 
any other Community Member State, if not their own 
country of origin, to work in biotechnology; 
5.3. organisation of training courses, summer schools and 
workshops, with support from the programme, and 
including participants from industry whenever possible. 
Where appropriate, representatives of other disciplines 
may also be invited to participate in these activities. 
The above criteria can be partially tested in 1993, but 
a further examination should be made in 1998. 
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3. Impact on the development of international 
4 . 
collaboration in biotechnology, particularly in the field of 
R&D, and including developing countries. 
Taking account of the results of Community, national 
or private sector research activities in biotechnology, it 
shall be considered whether the BRIDGE programme has: 
4.1. contributed to the application of the results of tne 
said research activities in the regions of the 
Community other than those in which the research was 
conducted; 
4.2. given adequate consideration to all the selection 
criteria set out in Annex III to Decision 
87/516/Euratom,EEC which includes that of contributing 
to the strengthening of the economic and social 
cohesion of the Community, while being consistent with 
the pursuit of scientific and technical excellence. 
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